Diabetes News

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c at 30 weeks for adults with type 1 diabetes, according to findings from the INHALE-3 extension trial.

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of an automated insulin delivery system compared with standard care, according to findings from a new trial.

The addition of glucagon-like peptide-1 receptor agonists to progestin therapy may help reduce endometrial cancer risk among certain women, according to study results.

Data from the Barbara Davis Center for Diabetes at University of Colorado show pilots with type 1 diabetes are not just thriving in the air, but also with their diabetes management.

The prevalence of obesity and diabetes has grown worldwide, presenting notable challenges to public health and health care systems.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.

Adults with type 1 diabetes who initiated treatment with a bionic pancreas at a primary care site experienced similar glycemic benefits as those starting the device through an endocrinologist, researchers reported.

TV watching in excess of 1 hour per day was associated with increased risk for atherosclerotic heart disease, independent of genetic risk for diabetes, according to new data published in the Journal of the American Heart Association.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial.